ORIC stock news · ORIC Pharmaceuticals
Get alerts for ORIC
Follow ORIC Pharmaceuticals (ORIC) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ORICORIC Pharmaceuticals shared its third quarter 2026 results, showing progress in its rinzimetostat program and strong cash reserves.
NeutralORIC reported $345.4 million in cash, expected to fund operations into the second half of 2028. Quarterly research spending rose to $43.4 million from $28.8 million, so this report leaves its outlook unchanged.
ORIC Pharmaceuticals shares new research on rinzimetostat at the ESMO Congress 2026.
Good for ORICORIC shared early findings suggesting rinzimetostat may offer advantages in prostate cancer treatment. The results support ongoing Phase 3 testing, making the news favorable, though patient benefit is unproven.
Oric Pharmaceuticals, Inc. shares new information about its drug trial and plans a bigger study for 2027.
Good for ORICORIC reported tumor shrinkage in its 26-patient enozertinib study, including in the brain, and plans a larger study for 2027. The results look promising, but need confirmation.
Oric Pharmaceuticals, Inc. shares new information about its drug trial and plans to start a bigger study in 2027.
Good for ORICOric reported early enozertinib results showing tumor shrinkage in many patients, including those with brain tumors. The study’s limits leave questions, but the news favors Oric.